These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 20731245)

  • 21. Transfusion-related transmission of yellow fever vaccine virus--California, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Jan; 59(2):34-7. PubMed ID: 20094025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody response to 17D yellow fever vaccine in Ghanaian infants.
    Osei-Kwasi M; Dunyo SK; Koram KA; Afari EA; Odoom JK; Nkrumah FK
    Bull World Health Organ; 2001; 79(11):1056-9. PubMed ID: 11731813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast.
    Fitzner J; Coulibaly D; Kouadio DE; Yavo JC; Loukou YG; Koudou PO; Coulombier D
    Vaccine; 2004 Nov; 23(2):156-62. PubMed ID: 15531032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yellow fever vaccination coverage among children in Brazilian capitals.
    Veras MA; Flannery B; de Moraes JC; da Silva Teixeira AM; Luna EJ;
    Vaccine; 2010 Sep; 28(39):6478-82. PubMed ID: 20674878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
    Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
    J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil.
    Suzano CE; Amaral E; Sato HK; Papaiordanou PM;
    Vaccine; 2006 Feb; 24(9):1421-6. PubMed ID: 16236402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis.
    Farez MF; Correale J
    Arch Neurol; 2011 Oct; 68(10):1267-71. PubMed ID: 21670384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.
    Veit O; Niedrig M; Chapuis-Taillard C; Cavassini M; Mossdorf E; Schmid P; Bae HG; Litzba N; Staub T; Hatz C; Furrer H;
    Clin Infect Dis; 2009 Mar; 48(5):659-66. PubMed ID: 19191654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of travel health advice in a French travel medicine and vaccine center: a prospective observational study.
    Bouldouyre MA; De Verdière NC; Pavie J; De Castro N; Ponscarme D; Hamane S; Rachline A; Ferret S; Molina JM
    J Travel Med; 2012; 19(2):76-83. PubMed ID: 22414031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
    Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
    Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Yellow fever--a tropical danger].
    Stingl P
    MMW Fortschr Med; 2004 Aug; 146(31-32):36-7. PubMed ID: 15529706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.
    Pereira RC; Silva AN; Souza MC; Silva MV; Neves PP; Silva AA; Matos DD; Herrera MA; Yamamura AM; Freire MS; Gaspar LP; Caride E
    Vaccine; 2015 Aug; 33(35):4261-8. PubMed ID: 25862300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine.
    Hepburn MJ; Kortepeter MG; Pittman PR; Boudreau EF; Mangiafico JA; Buck PA; Norris SL; Anderson EL
    Vaccine; 2006 Apr; 24(15):2843-9. PubMed ID: 16494976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.
    Kengsakul K; Sathirapongsasuti K; Punyagupta S
    J Med Assoc Thai; 2002 Jan; 85(1):131-4. PubMed ID: 12075714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viscerotropic disease following yellow fever vaccination in Peru.
    Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
    Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long term persistence of yellow fever neutralising antibodies in elderly persons].
    Coulange Bodilis H; Benabdelmoumen G; Gergely A; Goujon C; Pelicot M; Poujol P; Consigny PH
    Bull Soc Pathol Exot; 2011 Oct; 104(4):260-5. PubMed ID: 21336654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Yellow fever.
    Monath TP; Vasconcelos PF
    J Clin Virol; 2015 Mar; 64():160-73. PubMed ID: 25453327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy.
    Roukens AH; Vossen AC; van Dissel JT; Visser LG
    Vaccine; 2009 Apr; 27(18):2408-9. PubMed ID: 19368780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.